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The percent of people with mental health disorders in the United States have
skyrocketed over the past decade. With stigma surrounding the discussion of mental
health and the symptoms associated with it, often those that are suffering do not receive
sufficient treatment, as they might with a physical illness. The current, common
treatment options for common psychological disorders, like depression, anxiety, and
post-traumatic stress disorder, are sometimes not effective in patients, due to resistance
or poor response outcomes. Consequently, in order to research alternative therapeutic
approaches for mental health disorders, scientists are researching the effects of several
hallucinogenic drugs in controlled clinical environments as options. Drugs such as
MDMA, psilocybin, LSD, and ketamine are socially prohibited by law; however, some of
their benefits and mechanisms of action might have positive effects on treating the
disorders of the brain. This thesis provides a summary of mental illness, hallucinogenic
drugs, and the ongoing research regarding the use of these drugs in mental health
treatment. While the negative connotation around hallucinogenic drugs remains,
researchers are proving that they might have value in medicine, but the question
remains if science and society are ready to implement controlled hallucinogenic drug
therapies into mental health treatment based on the present research. The exploration
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Figure 1: Targets of the hallucinogenic drugs (LSD, MDMA, Ketamine, and Psilocybin)
within the body and their physiological effects
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Introduction
Mental health disorder rates have increased into a pandemic scouring the globe
affecting around 350 million people (De Gregorio et al., 2021). These types of disorders
manifest as impairments in a person’s thoughts, emotions, and behaviors. Common
examples of mental health disorders— and the ones that this thesis will be focusing
on— include depression, generalized anxiety disorder, post-traumatic stress disorder,
and obsessive compulsive disorder. Some of the symptoms in these disorders affect
virtually every individual at some point in their life, but they are only diagnosed as a
mental health disorder once they start to cause continual problems in one’s daily life,
career, and relationships (Gill et al., 2020). Unlike many physical diseases and
disorders, mental health disorders are still not fully understood. Research has shown
that mental illnesses are thought to be caused by a combination of genetic and
environmental factors. While these disorders can be inherited as parents pass down
their DNA to their offspring, stressful lifestyles, poverty, income, abuse, and more can
have a significant correlation with the development of mental health disorders in a
person (United Health Foundation, 2021). Since there are so many risk factors
associated with these illnesses, it makes it difficult for researchers, physicians, and
psychologists to discover the definite causes and manifestations of these disorders.
Unfortunately, with the hazy understanding in this area, the problem is getting worse.
Even before the pandemic, in 2017-2018, the prevalence of mental illness was
increasing with 19% of adults suffering, which was an increase of 1.5 million people
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since the year before (Mental Health America, 2021). There is an evident detriment
affecting the minds of many United States citizens, as well as others across the world.
Treating these disorders has also become an increasing problem with varying
side effects and growing resistance to the current prescriptions and therapies. Many
prescriptions are available in the treatment of mental illnesses, including
antidepressants, mood-stabilizers, anti-anxiety medications, and more. Oftentimes,
patients do not react as hoped to these prescriptions, and are therefore considered
treatment-resistant (Torres, 2020). This can be a very frustrating experience for people
who already are not feeling like their normal selves, as they have to use a process of
elimination with several different drugs that could give them undesirable side effects.
Therapy, whether group or individual, is also a common treatment for mental health
disorders, and is often used in conjunction with medication (Cuijpers et al., 2008). In
these scenarios, a trained therapist is able to talk with a patient about their problems,
feelings, and behaviors and suggest ways to positively react or think in varying
situations (Cuijpers et al., 2008). Since there has been a trend in resistance and
inadequate treatment, researchers have started looking elsewhere for alternative
methods to manage mental health disorders. In particular, there is emerging evidence
that using several hallucinogenic drugs in varying methods has a positive impact on
mental health illnesses like major depressive disorder, post-traumatic stress disorder,
generalized anxiety disorder, and obsessive compulsive disorder (De Gregorio et al.,,
2021). In this thesis, a proposal will be made on the usage, legalization, and effect
these new therapeutic methods could have on science and society.
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Mental Health Disorder Backgrounds
Major Depressive Disorder
Major Depressive Disorder (MDD) is considered a common, yet serious mental
condition affecting one’s thoughts and/or behaviors in a negative manner. Common
symptoms of MDD include frequent sadness, loss of interest in activities the individual
once enjoyed, abnormal sleeping habits, difficulty concentrating, suicidal thoughts, and
more (Torres, 2020). Oftentimes, the presented symptoms impair a person’s ability to
efficiently function within their career, schoolwork, relationships, and many aspects of
daily life. In order to be diagnosed with MDD, one must have experienced one or more
of the symptoms for at least two weeks leading to changes in behaviors and
impairments in one’s life (Torres, 2020). In 2019, 19.9% of adults in the nation were
reported being diagnosed with MDD (United Health Foundation, 2021). These statistics
only show those that were officially diagnosed, so the actual percentage is likely much
higher. In addition to this, nationally women are much more likely to suffer from
depression than men, and studies have proven that one-third of women will experience
a major depressive episode at least once in their lifetime (Torres, 2020). The likelihood
of developing depression at some point in an individual’s life is very high and provides
justification that ample research should be conducted on therapeutic methods to at least
ease the symptoms.
Unfortunately, we do not fully understand the risks or direct causes of
depression. There is evidence that genetics plays a role in how likely it is that someone
will develop MDD. For example, if a parent or sibling is diagnosed with depression,
there is a 40% chance that one has inherited the gene causing the illness will progress
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in them as well (Torres, 2020). In addition to this, if an identical twin has MDD, the other
twin has a 70% chance of developing the illness at some point in their life (Torres,
2020). These statistics clearly show that there is some level of heritability and
gene-dependence in MDD. There are also various environmental factors that are shown
to have an effect on the probability of depression at some point in an individual's life. If a
person has experienced a form of trauma, such as violence, abuse, or neglect at any
point, they are much more at risk for moderate to severe depression affecting their life
(United Health Foundation, 2021). Poverty is also considered to be a common and
grave threat to the development of MDD. Income and depression are statistically shown
to have an inverse relationship, meaning that as one falls into poverty or a lower income
bracket, they have a higher chance of battling depression (Torres, 2020). Minor
grievances like stressful careers and lifestyles also can play a role in progression of the
disorder. Mental health professionals have clearly stated, however, that sadness and
grief are not necessarily the same as MDD. For example, if someone enters a period of
sadness and low activity while mourning the loss of a loved one, they should not be
immediately diagnosed with depression, as the affliction is expected to subside
eventually without medical intervention. In addition to the aforementioned risks, the
symptoms of depression can result from an imbalance of neurotransmitters between
nerve cells in the brain. Neurotransmitters are chemicals that are released from nerve
cells to communicate with one another, so when they are not doing their job correctly,
the brain is not responding as it should (Jelen & Stone, 2021). This can lead to the
common symptoms of MDD.
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Depression is one of the most treatable mental health disorders. In order to
diagnose MDD, a psychologist or psychiatrist will interview a patient and perform a
physical exam, and often a blood test to ensure depressive symptoms are not due to an
alternative condition like thyroid problems or a vitamin deficiency (Torres, 2020).
Medications like selective serotonin reuptake inhibitors (SSRIs) and
serotonin-norepinephrine reuptake inhibitors (SNRIs) are considered first-line
treatments, but 50% of MDD patients fail to respond to these prescriptions (Gill et al.,
2020). Furthermore, it has been found that 42% of individuals stop antidepressant
prescriptions after one month of use, and an even more staggering 72% discontinue
within the first 3 months (Gill et al., 2020). Both of these drug classes work to prevent
the reuptake of certain neurotransmitters in the brain. As stated before,
neurotransmitters are messenger chemicals that are released from nerve cells. Once
released, the neurotransmitters are commonly absorbed back into the nerve cell from
which they were expelled. SSRIs and SNRIs work to stop the reabsorption process so
that the neurotransmitters stay between the communicating nerve cells for a longer
period of time (Newcomer et al., 2000).. In this way, antidepressants have the capability
to modify an individual's chemistry of the brain without directly sedating or stimulating
them.
Oftentimes, the use of psychotherapy is often applied alongside antidepressant
prescription. This is often manifested as the stereotypical therapist one-on-one
conversation with a patient. Cognitive behavioral therapy (CBT) is very common and
can aid a person in acknowledging their negative thinking and works to alter those
thoughts to respond to situations in a different, more positive way. Cuijpers et al. (2008)
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defines CBT objective as “aimed at evaluating, challenging, and modifying a patient’s
dysfunctional beliefs (cognitive restructuring).” In this way, the therapist focuses on
teaching a patient alternative ways to cope and giving specific objectives for the patient
to work on outside of their sessions. There are other forms of therapy that are also
effective in relieving depressive symptoms and educating an individual how to better
handle their diagnosis, including group therapy and social skills training (Cuijpers et al.,
2008). If a person fails to respond to prescriptions or various forms of psychotherapy,
some psychiatrists might recommend the use of Electroconvulsive Therapy (ECT). ECT
can be used for depression treatment by applying electrical current to a patient's scalp
to alter brain activity. The remission rate has been found to be a wide range from 20%
to 80% depending on performance (Lisanby, 2007). However, this treatment can cause
some severe side effects, including retrograde amnesia, meaning the individual can
experience gaps in their memory from events that occurred months to years before the
treatment (Lisanby, 2007). Clearly, the available treatments for depression are not
perfect so further research is required to continue helping those that suffer the illness.
Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder (PTSD) is a condition resulting from the
exposure to a negative life-altering or traumatic event. Oftentimes, this traumatic
experience can be related to loss after a natural disaster, being a victim of sexual
assault, military combat, or other life-threatening occurrences (Torres, 2020). PTSD can
develop at any age, but diagnosis requires the awareness or involvement in a
distressing event as explained above (Mayo Clinic, 2018). Consequently, the individual
did not necessarily have to be directly exposed to the event, so someone that has been
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subjected to hearing about certain personal or repeatedly upsetting events could be
affected by PTSD. Depending on the event the person experienced, they might have
related flashbacks or nightmares, as well as avoid other situations that have the
possibility of reminding them of the trauma (Mayo Clinic, 2018). Common symptoms of
PTSD fall into the categories of intrusion, alterations in cognition and mood, avoidance,
or alterations in arousal and reactivity (Torres, 2020). Intrusion manifests as thoughts
that bring back memories or flashbacks from the event that can be severe enough for
the individual to believe they are reliving it. When an individual starts to believe
misrepresentations about themselves, others, or the cause of the event, they are
considered to have altered cognition. In addition to this, they can start to feel detached
from people around them and the activities they used to appreciate. Avoidant behavior
is similar to this and occurs when a person circumvents talking about the traumatic
event or including themselves in situations that might trigger them. If an individual
sometimes erupts in anger or self-destructive behavior and experiences issues
focusing, their reactivity might be changing in response to the trauma (Torres, 2020).
Young children that are demonstrating PTSD symptoms might have nightmares or may
act out scenes of the event while playing (Mayo Clinic, 2018).
PTSD symptoms can present days to years after the individual experiences the
upsetting event, and eventually causes problems in daily life. It is estimated that one in
11 people will develop PTSD over their lifetime (Torres, 2020). Treatment can help a
suffering person control their symptoms and not let their illness take over their life. The
most common form of treatment for PTSD patients is psychotherapy, which as
previously described can involve cognitive therapy where a therapist teaches new
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coping mechanisms and thought processes to handle distorted beliefs that have
developed. Another form of psychotherapy that is often used for PTSD patients is
exposure therapy. In this type, trained professionals introduce situations that might
trigger the patient through discussions or virtual reality to find healing through direct
coping (Taylor et al., 2003). Eye movement desensitization and reprocessing (EMDR)
can be used through teaching external oscillatory stimulation, often by a therapist
directing the patient’s eye movements with their finger, to reduce distress when recalling
traumatic experiences (Taylor et al., 2003). PTSD therapies can be reinforced by use of
medications like antidepressants, anti-anxiety prescriptions, and the drug prazosin. The
Mayo Clinic (2018) suggested that prazosin has been found to reduce PTSD-related
nightmares in some studies, but has shown no benefit compared to a placebo in others.
Post-traumatic stress disorder is more prevalent in our society than the movies might
portray specifically in the context of military veterans. While those groups of people can
still be heavily affected by PTSD, there are many other cases and situations in which
someone might suffer from this disorder, lending to the idea that more research needs
to be done on effective treatment options.
Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD) is often misunderstood as common stress
and anxiety that people feel on a day-to-day basis; however, it is much more serious
and complex. Anxiety disorders are often found in people that also suffer from MDD,
with estimates as high as almost 42% (Gill et al., 2020). People suffering from GAD are
overcome with feelings of nervousness and worry with often little reason behind it. This
unease often leads to disruption in lifestyle and completing tasks. GAD can manifest not
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only through psychological symptoms such as lack of concentration, restlessness, and
constant worry, but also through physical symptoms such as excessive sweating,
twitching, or stomachaches (Anxiety & Depression Association of America, 2021)..
These symptoms, along with many others, often escalate in times of crisis or increased
stress, including conflict within friendships or family. In order to differentiate persistent
GAD from common stressors, an individual must experience this irrational anxiety for a
majority of 6 months with 3 or more symptoms showing (Anxiety & Depression
Association of America, 2021). Another helpful distinction is the lack of control that
many with GAD feel. Often, normal anxiety can be related to stressful events in life but
is limited to a short time period and can be managed by relaxation and other simple
techniques that do not require medical intervention. GAD is known to develop over an
individual's lifetime and may not be diagnosed until adulthood (Gill et al., 2020). In the
United States, 6.8 million adults are affected by GAD each year, with women being
much more likely to suffer (Anxiety & Depression Association of America, 2021). As
indicated in other mental health disorders, the root cause of GAD is not fully understood
but can be related to family history and inherited genes, biological factors, and
environmental stressors.
Treatment for Generalized Anxiety Disorder includes many of the already
discussed methods, such as cognitive behavioral therapy and prescriptions for SSRIs
(Gill et al., 2020). In addition to these treatments, benzodiazepines can be prescribed
for serious cases of GAD. These drugs are sedatives that can rapidly manage
symptoms of anxiety disorders, but often present a long list of side effects that can be
just as harsh as the disorders themselves, including depressive feelings, confusion,
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dizziness, irritability, and more. Unfortunately, use of benzodiazepines can lead to heavy
dependence and withdrawal symptoms if an individual suddenly stops taking the
medication (Martin et al., 2007). While this prescription can be a fast-acting relief for
GAD patients, the eventual outcome might outweigh the transient solace.
Obsessive Compulsive Disorder
Abnormal obsessions, compulsions, or both can be indicators of Obsessive
Compulsive Disorder (OCD). Often, OCD is diagnosed while an individual is still in their
teenage years, but can still be found later in life. Obsessions are thoughts that lead a
person to unnatural urges or ideas, including the belief that everything must be perfect,
adverse thoughts about social norms, or phobia of germs (National Institute of Mental
Health, 2019). These obsessive feelings can lead to disruption in relationships or job
performance. Compulsions, on the other hand, are often repeated behaviors that
manifest due to the obsessions (National Institute of Mental Health, 2019). These
ritualistic actions can be uncontrollable and cause distress in the individual performing
them. For example, if a person has obsessive thoughts surrounding the idea of bacteria
contaminating their life, they might compulsively clean their house and wash their hands
excessively throughout the day. Commonly, patients that suffer OCD are also diagnosed
with a tic disorder which can be motor or vocal in nature. Motor tics are physically
repeated movements like jerking, blinking, or grimacing, while vocal tics can include
sounds like sniffing or grunting (National Institute of Mental Health, 2019). OCD
symptoms can be devastating when the patient knows their actions are not normal or
healthy, but still cannot stop the behaviors.
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As mentioned in the introduction of the mental health disorders above, the cause
of OCD is not known, but risk factors are often associated with environmental
influences, past trauma, genetics, and abnormal brain functioning (National Institute of
Mental Health, 2019). In order to treat OCD effectively, a patient must also be screened
for a combination of other mental health disorders. As in most cases, OCD patients can
be introduced to psychotherapy to ease their symptoms. A specific type of CBT is often
used in OCD cases called Exposure and Response Prevention (EX/RP). In this method,
a patient is brought into an environment where they are exposed to triggering situations
and then restricted from performing the related compulsive behaviors (Thordarson et al.,
2004). An example of EX/RP might be walking into a room where all of the lights and
appliances are turned on, then being escorted out without being allowed to turn off or
unplug any items. In addition to psychotherapies, patients are often prescribed
medications like SSRIs, which are usually given in higher doses to OCD individuals
compared to other disorders (Pittenger & Bloch, 2014). Correspondingly to the
aforementioned mental health disorders, these treatment options are not always
successful or efficient in managing symptoms so researchers are studying new
alternatives.
Hallucinogenic Drugs
Hallucinogenic drugs are a specific class of drugs that can modify the way an
individual perceives their five senses as well as changing their thoughts and behaviors
(De Gregorio et al., 2021). If a high enough dose is taken, the drugs can cause a person
to hallucinate, meaning they will feel or see things that are not really present. They are
generally categorized by their effects on central nervous system targets that lead to
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redirection of brain communication (Sherwood & Prisinzano, 2017). There are two
categories of hallucinogenic drugs: dissociative anesthetics and serotonergic classic
hallucinogens, which are commonly referred to as psychedelics. Dissociatives, like
ketamine, are believed to act on the glutamatergic system, while psychedelics, like
psilocybin, exert agonistic effects on the 5-HT system, also known as serotonin
receptors (De Gregorio et al., 2021). Serotonergic receptors are known to play a role in
cognition, perception, and attention, so when increased, the effects can lead to
psychedelic experiences. After taking either type of hallucinogen, the effects can start
happening within minutes and could last anywhere from a few hours to days (Sherwood
& Prisinzano, 2017). Hallucinogens contain a wide variety of specific drugs, each
working a little differently than the next and most having an intended medical or
practical use; however, as with most drugs, some individuals choose to abuse
hallucinogens and use them “recreationally.”
The Drug Enforcement Administration (DEA) has listed most of the
hallucinogenic drugs under a Schedule I classification in the Controlled Substances Act.
This means that the drugs have no accepted medical use in the US and are considered
likely to be abused (Drug Enforcement Administration, 2020). Consequently, the drugs
are illegal when used in recreational settings, rather than if they have some sort of
approved medical application, such as ketamine being used as an anesthetic in an
operating room. Although the DEA has indicated many hallucinogens as high abuse
potential, they are not necessarily considered addictive. If a person was using
hallucinogenic drugs on several occasions, they will not experience withdrawal
symptoms or cravings to return to use like in the disease of addiction (U.S. Department
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of Justice, 2020). Nevertheless, as with many drugs, hallucinogens are widely known to
lead to tolerance, meaning that with continued use, a higher dose of the drug is required
to produce the same effect (National Institute on Drug Abuse, 2019). The lack of
addictive quality in many hallucinogens makes them valuable for research potential in
treating illnesses. The negative effects of long-term, unregulated use of psychedelics
and dissociatives is not fully known, but it is expected that they are not common. Classic
hallucinogens have been found to lead to Persistent Psychosis and Hallucinogen
Persisting Perception Disorder, which in general lead to altered mental state and
flashbacks of past drug experiences, respectively (National Institute on Drug Abuse,
2019). Most often, the concern with hallucinogenic drug usage is the indirect effects that
could occur due to the modified perception and mood that do not correspond with reality
(U.S. Department of Justice, 2020). For example, if an individual was under the
influence of LSD, commonly referred to as “acid,” they might be more likely to indulge in
risky behavior like jumping from dangerous heights because of their altered
consciousness.
Although hallucinogenic drugs carry a negative connotation due to their abuse in
recreational drug usage, researchers are studying the potential positive effects these
types of drugs could have on mental health disorders, like the ones mentioned above.
As described, both categories of hallucinogens act on systems in the brain that are
closely related to the development of mental illnesses. Low levels of serotonin and
glutamatergic metabolites are linked to depression symptoms, along with other mood
disorder effects; by the actions of hallucinogenic drugs, there might be potential to help
treat these types of disorders (Torres, 2020).
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Ketamine
Ketamine falls under the dissociative category of hallucinogens and is a synthetic
drug with anesthetic and analgesic properties. Due to this reason, ketamine is used as
an anesthetic in operating rooms and trauma situations (Jelen & Stone, 2021). The drug
is a noncompetitive NMDA receptor antagonist, meaning it can bind to a site on this
receptor making it unable to activate properly (Figure 1). The NMDA receptor is a
glutamate-gated ion channel that specifically plays a role in memory formation,
breathing, and movement, so when ketamine prevents the activation of this receptor, it
can produce psychotic symptoms that include dissociation and memory impairments
(Newcomer et al., 2000). The dissociation caused by ketamine usage includes feelings
described as “out-of-body” experiences, as well as hallucinations, confusion, and
intense relaxation. Ketamine can be taken orally or intravenously, and the effects can
become present anywhere from one to 30 minutes depending on mode of
administration. Furthermore, lingering effects can occur for up to a day after delivery
(Alcohol and Drug Foundation, 2021). While ketamine is illegal to be used recreationally
due to its dangerous side effects that can occur when unregulated, its medicinal value is
already recognized in many settings and applications.
MDMA
MDMA, which is scientifically named 3,4-methylenedioxymethamphetamine, is
the active ingredient in the illicit drug ecstasy. When administered into a body, it has a
very quick absorption rate and after it crosses the blood-brain barrier, its effects can be
felt rapidly and include euphoria, heightened sociability, and a generally happy state
(Liechti et al., 2001). This synthetic drug has the capability of distorting time and
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surroundings for the user, much like other hallucinogenic drugs. Although many articles
and experts explain that MDMA exhibits similar effects to both stimulants and
hallucinogens, it has also been categorized as a member of another class referred to as
entactogens. While many drug classes are closely intertwined in many ways,
entactogens are commonly related to feelings of pleasure, empathy, and relaxation due
to their properties of releasing and inhibiting reuptake of serotonin (Gouzoulis-Mayfrank,
2001; Figure 1). In addition to this, MDMA has the capability of releasing dopamine,
norepinephrine, and oxytocin as well (De Gregorio et al., 2021). Before MDMA began to
be sold recreationally as a “party drug,” it was originally synthesized for pharmaceutical
purposes. In 1912, a German scientist formulated MDMA in hopes to produce a
blood-clotting agent, preceding use of the drug in many psychotherapy trials in the
1960s and 1970s, before it was officially labeled as a Schedule I drug in the Controlled
Substances Act, thus requiring FDA approval for further research (Passie, 2018). The
intense and popular study of MDMA because of its unique psychological properties in
the mid-to-late 20th century shows great potential for its therapeutic effects; present and
future research might lead to the same conclusion.
Psilocybin
Unlike ketamine and MDMA, psilocybin is a naturally-occurring substance that
exhibits changes in perception, cognition, and behavior. Users can experience
hallucinations, as well as distortions in time and location, increased creativity, intense
emotions, and a playful euphoria, with relatively low outcomes of harm (Kargbo, 2020).
Kargbo further explains that psilocybin is considered a psychedelic, or classic
hallucinogen, that works by activation of the serotonin 5-HT2A receptors leading to
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awareness in the hallucinatory state (Figure 1). Psilocybin is found in “magic
mushrooms” which can be ingested and then metabolized to the main, active ingredient
psilocin, which contains psychoactive, or mind-altering properties (Al-Naggar et al.,
2021). In the past, psilocybin has been popular in history during spiritual ceremonies,
but was not prohibited in the United States. Psilocybin is not an addictive drug and does
not lead to dependency, withdrawal symptoms, or any severe physical effects after
continued use (Kargbo, 2020). Due to these findings, the drug, commonly referred to as
“shrooms” in illicit, recreational use, has researchers considering positive effects in
psychotherapy because of that receptor's role in anxiety and depression manifestation.
LSD
Another classic hallucinogen, LSD (lysergic acid diethylamide) is very potent in
its side effects of hallucinations, distorted sense of vision and hearing, and euphoric
state. Much like psilocybin, LSD acts as a serotonin 5-HT2A receptor agonist, but it also
has affinity for several dopamine receptors as well (De Gregorio et al., 2021; Figure 1).
LSD is not generally considered high on the list of unsafe drugs since it does not lead to
severe long-term effects or withdrawal symptoms after use; however, if an individual
experiences a “bad trip,” meaning the drug causes disturbing hallucinations or anxiety, a
person might be at higher risk of committing unsafe behavior while under the influence
(U.S. Department of Justice, 2020). Synthesis of LSD occurred first in the 1930s by a
Swiss chemist who absorbed part of an ergot fungus through his skin, then felt intense
hallucinations and kaleidoscope-like visions from the active ingredient in LSD, lysergic
acid (Dyck, 2015). Not long after, LSD found its way to raves and other party
atmospheres, leading to its Schedule I listing and illegalization. Nevertheless, the
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potential therapeutic properties of LSD are recognized and researched for
psychotherapy methods.
The general negative reputations of hallucinogens as party drugs or illicit
recreational activities hinders them from widespread research and gaining therapeutic
authorization. The abuse of these drugs for non-medical purposes has led to their
Schedule I classification by the DEA and criminalization. Although the recreational use
of the drugs have stigmatized them for the general public, some unconventional, unsafe
research has caused them to be condemned in the medical community as well. For
example, psychologist Timothy Leary researched the effects of LSD and psilocybin at
Harvard University. Leary was considered the Father of the Psychedelic Movement of
the 1960s (NPR, 2020). At Harvard, Leary conducted investigations that did not follow
research guidelines, such as being under the influence of hallucinogens during
research, promoting recreational use, and administering the drugs to subjects that were
not supposed to be included in the research, such as undergraduate students. Due to
the violations, Leary was fired from Harvard leading to a stigma surrounding the
research of hallucinogenic drugs (Harvard University, n.d.). Before the implementation
of hallucinogens into medicine occurs, destigmatization will have to take place so the
drugs are more widely accepted.
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Figure 1. Targets of the hallucinogenic drugs (LSD, MDMA, Ketamine, and Psilocybin)
within the body and their physiological effects. Adapted from “Hallucinogens in Mental
Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine,” by
De Gregorio et al., 2021, The Journal of Neuroscience, 41(5), 892.
Discussion of Hallucinogenic Drug Treatments
Hallucinogenic Drugs in the Treatment of Major Depressive Disorder
The use of psilocybin and ketamine have both been found to have positive
potential in treating MDD in many research studies. In fact, despite its Schedule I
classification in the Controlled Substances act by the DEA, psilocybin has been granted
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Breakthrough Therapy status by the Food and Drug Administration for its use in the
treatment of MDD, especially treatment-resistant MDD (Kargbo, 2020). This distinction
signifies that psilocybin has potential and displays advantages over other current
treatment options for MDD, including prescription SSRIs. Many studies have found
therapeutic benefits of psilocybin to last for a significant period of time, and in some
cases following only a single dose. In one study with participants suffering from
treatment-resistant MDD, depressive symptoms were relieved significantly following
psilocybin treatment in conjunction with psychotherapy sessions. In this trial, doses of
10 mg and 25 mg were administered 7 days apart, meaning that even after only one
week with psilocybin-assisted therapy sessions, symptoms were reduced (Gill et al.,
2020). Even further, the statistically significant reduction of depression was found to last
for up to 4 weeks in 71% of MDD patients in another clinical trial (Barrett et al., 2021).
Many other studies have found similar results in the effectiveness of psilocybin on MDD
statistically significant improvements of depression symptoms quickly and for much
longer than the traditional methods of medication.
The rapid onset and sustained effectiveness of ketamine infusions may be
advantageous as a treatment option for MDD. A single infusion of ketamine has been
found to reduce depressive symptoms over the course of just a few hours and has the
capability to last from the range of days to weeks (Barrett et al., 2021). These efficacy
statistics put it above common treatments of MDD, like SSRI medications and simple
psychotherapy which take many administrations and much longer time periods before
significant improvements emerge. Due to this, intravenous ketamine infusion treatment
clinics are offered across the United States; however, other methods of infusion, such
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as oral medication or nasal spray, have also been found to be practical with positive
effects, especially when used alongside an antidepressant (Jelen & Stone, 2021). Since
ketamine is already used medically for anaesthetic purposes, the available ketamine
clinics are legal, but not FDA approved for treating depression. Oftentimes, these
websites fail to mention the lack of FDA certification unless an individual thoroughly
investigates its content. For example, Serenity Health, located in Louisville, Kentucky,
mainly refers to their business as “Anesthesia Infusion” rather than “Ketamine Infusion,”
and does not mention lack of FDA approval other than after the 8th question under the
FAQ tab (Serenity Health, 2018). Nevertheless, scholarly research has shown
therapeutic benefits of ketamine infusions. One study with 73 treatment-resistant MDD
patients found a statistically significant reduction in depressive symptoms 24 hours after
intravenous ketamine administration compared to the placebo group. In this particular
experiment, the placebo was the benzodiazepine, midazolam, which is considered an
active placebo due to its sedative and anxiolytic effects (Jelen & Stone, 2021).
Although clinical setting doses are notably less than most recreational user doses,
caution should be exercised when administering ketamine. Chronic, recreational use of
ketamine has been found to lead to impairments in working and episodic memory, which
could negatively impact the support for its use in mental health treatment (Jelen &
Stone, 2021). Altogether, with clinically safe and monitored doses of ketamine, the
research and implementation of ketamine infusion therapy has been very positive and
beneficial for MDD patients.
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Hallucinogenic Drugs in the Treatment of Post-Traumatic Stress Disorder
It is known that PTSD patients risk high rates of treatment drop-out, in addition to
common resistance to current accepted methods of treatment for their condition (Torres,
2020). Consequently, the identification of new potential drugs and remedies is
necessary for this often long-term disorder. The increased effect that MDMA has on
trust and social connection, as well as its reduction of memories related to traumatic
events and fear could make it a promising candidate for disrupting the symptoms of
PTSD (De Gregorio et al., 2021). Many studies have focused on the correlation
between MDMA-assisted psychotherapy and PTSD symptoms, leading to a wide variety
of research conclusions and suggestions on its implementation. Much like psilocybin for
use in MDD treatment, MDMA has been granted Breakthrough Therapy status by the
FDA for research with PTSD. Consequently, there are currently Phase 3 clinical trials
being conducted studying MDMA-assisted psychotherapy, meaning its legalization and
use might not be far in the future (De Gregorio et al., 2021).
Current research has shown significant improvements in PTSD patients following
a long-term checkup post-MDMA-assisted psychotherapy, with no associated cognitive
impairments or negative side effects, such as increased blood pressure. (Gill et al.,
2020). The lack of side effects and reduction of symptoms trump some of the current
options and medications used in PTSD treatment that lack fundamental support and
concrete effects. In the aforementioned trial, chronic PTSD patients received two active
doses (100mg and 125mg) of MDMA over the course of an 8 hour psychotherapy
session. This administration demonstrated significant improvements in symptoms, even
at the 12-month follow-up appointment (Gill et al., 2020). The sustainability of MDMA
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over a long period of time shows its efficient execution in diminishing PTSD symptoms,
which is highly efficacious over the current options that are prone to resistance.
Studies against the placebo effect have also seen promising results. In one
experiment by Vermetten and Yehuda, patients diagnosed with PTSD underwent three,
8 hour psychotherapy sessions each spaced a month apart (2019). The two groups
were either given an active dose of MDMA or a placebo that caused similar
entactogen-like effects. The MDMA patients recorded a significant reduction in PTSD
symptoms over the placebo patients, and subsequent sessions found twice the MDMA
patients lacking the criteria to even meet PTSD diagnosis (Vermetten & Yehuda, 2019).
Overall, the effects that MDMA studies have illustrated on the disruption of PTSD
symptomology is astounding and highly successful.
Hallucinogenic Drugs in the Treatment of Generalized Anxiety Disorder
Often, Generalized Anxiety Disorder is grouped together, or comorbid, with other
mental health disorders, making it difficult to research by itself; however, many studies
have been conducted on the effect of hallucinogens on anxiety induced by diagnosis
with a life-threatening illness. One study found that cancer patients suffering from both
anxiety and depression felt statistically significant relief for up to 6 months following a
therapeutic single-dose of psilocybin combined with psychotherapy (Greer, 2011). In the
previous study, patients were officially diagnosed with both GAD, as well as other
anxiety disorders due to cancer diagnosis. These promising results show that the use of
psilocybin in conjunction with other forms of therapy might have similar effects on
non-cancer patients as well. Another study found comparable results, with patients with
various life-threatening illnesses finding alleviation of anxiety symptoms for up to 6
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months after a one-time dose of psilocybin (McCorvy et al., 2016). Between these two
studies, different control compounds were employed, with psilocybin maintaining
significant results over both, substantially reducing the likelihood of placebo effect. The
use of psilocybin for anxiolytic effects seems to have great potential based on available
data.
Along with psilocybin psychotherapy, LSD-assisted psychotherapy has been
found to lead to positive improvements in patients diagnosed with life-threatening
illnesses. After completing therapy in conjunction with a medical dose of LSD, 77.8% of
participants were found to maintain reduced anxiety for 12 months following the
treatment, along with 66.7% that reported a rise in quality of life (Gasser et al., 2014).
Due to similarities between psilocybin and LSD, the potential for both seems to make
sense scientifically. Further studies might be required in patients diagnosed with anxiety
who are not suffering from life-threatening illnesses. Although that is the scope of the
research so far, some would argue that if the use of these classic hallucinogens can
relieve that significant level of anxiety-induced by life-threatening illness diagnosis, they
should likely produce similar results in GAD with no associated physical illnesses.
Hallucinogenic Drugs in the Treatment of Obsessive Compulsive Disorder
The effects of hallucinogenic treatment on OCD patients has not been thoroughly
researched enough to indicate there is sufficient evidence supporting its use. As
explained above, OCD is believed to be caused by defects in the 5-HT (serotonergic)
system, so scientists see the possibility of psilocybin’s potential therapy for these
patients. Of the few reported studies, a general case study was documented of a
38-year old man who had chronic anxiety and symptoms of obsessive compulsive
23
disorder. He outlined that he had tried several forms of psychotherapy and prescription
medication that had little effect on reducing his symptoms. Once the subject consumed
“magic mushrooms” and fell into the habit of taking two grams of these mushrooms
every three weeks, he experienced relief from his intrusive thoughts and anxiety
(Wilcox, 2014). Although this patient had no scientific testing done on the mushrooms
he was consuming, it is likely they were psilocybin-type.
Further studies by professional researchers have found more positive results with
the effect of psilocybin on OCD symptoms. In one small-sample experiment, nine OCD
treatment-resistant subjects were given single-dose psilocybin varying in dosage. There
was no psychotherapy in conjunction with the drug, although the study took place in an
outpatient clinic. In every patient, OCD symptoms were significantly reduced
immediately and maintained that way for around 24 hours even after the psychedelic
effects diminished (Majić et al., 2015). In order to deem any sort of hallucinogenic drug
safe to treat obsessive compulsive disorder, studies with larger sample sizes and
multiple dose administrations need to be executed. Due to their similar mechanisms of
action, LSD should be considered as a route of study for OCD treatment along with
psilocybin.
Conclusion
After analyzing the available research and studies encompassing the topic, the
question remains if these drugs should be widely used in mental health treatment. As in
any experimental findings and new treatment approaches, extreme caution and
thoroughness needs to be explored before implementation. This situation is no different.
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For example, some hallucinogenic drugs are known to lead to toxic effects or physical
impairments if used chronically in unrestricted doses. MDMA has the ability to cause
deficits in memory and attention (Gill et al., 2020). Due to this, extensive research is
necessary to determine if clinical doses of MDMA would cause damage to forebrain
structures leading to these issues in the long-term. Furthermore, ketamine is associated
with bladder and neurologic toxicity with persistent use, so there should be assurance
that the treatment plans would not cause these problems in patients, or at least would
not be used long enough to lead to possible complications (De Gregorio et al., 2021). In
a medical setting, it is likely that most of these drugs would not cause damaging effects
from clinical doses, in contrast to unregulated, recreational environments which might
pose more risk.
Another major concern with these drugs is the likelihood that the placebo effect
might be in play during trials, with no significant way to circumvent it. The described
drugs cause very distinct hallucinogenic and dissociative effects, so when patients are
in the control or drug group, they likely will be able to tell either way. A major factor in
ensuring drug efficiency is blinding during research and ruling out the placebo effect;
however, this becomes a challenge when there are other commonly known side effects
of these drugs. While some trials have resorted to the typical “sugar pill” as a placebo,
many others have tried to combat this obstacle by using drugs that have somewhat
similar disorienting effects to the subject drug or using lower doses of the drug in
question (Jelen & Stone, 2021). Much of the current research demonstrates that the
drugs reduced symptoms significantly compared to placebo, but there should be a
guarantee that blinding was successful before that claim is made. Finally, the negative
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social connotation that hallucinogenic drugs hold makes it difficult for them to be
accepted as medically-safe. Currently, these drugs are widely known by their street
names, like shrooms, ecstasy, and more, which automatically leads someone to think of
their illegal, recreational use. In addition to this, the Schedule I classification of
psilocybin, MDMA, and LSD limits their ability to be widely accepted in medical
treatments, hindering their potential benefit.
While there are obstacles that restrict LSD, psilocybin, ketamine, and MDMA to
be universally welcomed in the medical community, they each have many positive
attributes as well. Most notably, trials with each of these drugs has shown that one, or a
few, administrations of clinically-acceptable doses can relieve symptoms quickly and for
much longer when compared to current treatment options, like therapy or prescription
medications. For example, in a study involving psilocybin in MDD treatment it was found
that, “a single acute exposure to the hallucinogenic agent can elicit an immediate and
lasting improvement in symptoms for the patient, an effect that persists long after the
drug is metabolized and gone from the body” (Sherwood & Prisinzano, 2017). SSRIs
and other antidepressant medications require chronic, daily dosing regimens in order to
stay effective for a patient, and oftentimes individuals are resistant to many first-line
treatments (Gill et al., 2020). Moreover, with fewer doses of the drugs lasting a long
period of time, there will be a significant reduction in healthcare costs for a patient in the
long run. The extensive positive results that have been demonstrated most remarkably
for MDMA in PTSD treatment and psilocybin in MDD treatment cannot be ignored and
outweigh current courses of treatment in almost every category.
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In order to eventually implement these drugs into mental health disorder
treatment, education and guidelines need to be widely regulated to smoothly transition
these drugs in the medical community. For example, clear examples need to be shared
of how the drugs would be administered and how dosing would work. Most likely, a
psychotherapy session would be accompanied by drug dispensing, which would be
administered by a nurse, psychologist, or psychiatrist that has attended updated training
on the use of the drugs. The environment of the session would be a comfortable and
familiar clinical setting, facilitated by a guide that could reduce any negative
hallucinations or thoughts that appeared during drug peaks. The dosage would likely be
several orders of magnitude less than unregulated recreational users, allowing for a
more controlled, safe experience. Another important way to reduce the stigma regarding
hallucinogens in medicine is to reclassify them under the DEA scheduling system so
that the therapeutic effects can be fully investigated without restriction or negative
connotation. Currently in the Controlled Substances Act, the Schedule I classification
describes the drugs as having no accepted medical use; however, it has been shown in
the aforementioned research and more that the drugs have beneficial potential as a
mental health remedy, so that claim has been refuted. The Controlled Substances Act
also becomes contradictory in its application because even with the current scheduling,
the illegal drugs are permitted to be used solely for medical research purposes. There is
evident inconsistency in the classification requirements and the authorization of clinical
usage. Due to this, the drugs should be destigmatized as much as possible. By
recognizing this medical value and classifying them under a different schedule, MDMA,
psilocybin, and LSD would be more widely investigated and accepted in clinical settings.
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Compassionate use is another available policy for utilization of these
unauthorized drugs that might be helpful until they are approved by the FDA. In this
practice, often also called expanded access, physicians would have the capability to
implement investigational treatments for patients that are living with serious diseases if
alternative therapies are not working (Greif & Šurkala, 2020). Since it is a physician’s
duty to provide the best, fulfilling care for their patients, they would be able to utilize
medications, such as these hallucinogenic drugs, outside of an enrolled clinical trial.
There has been published research illustrating that, at least for use of psilocybin and
MDMA, implementation into treatment programs are rational and ethical in the
healthcare community after examining their safety and efficacy (Greif & Šurkala, 2020).
While it might sound alarming to treat someone with a drug that is not approved, for
many suffering from MDD and PTSD symptoms, doing nothing could be far more
harmful.
Overall, the research and ongoing clinical trials demonstrate that use of the
psychedelics and dissociatives, LSD, MDMA, psilocybin, and ketamine are promising in
the treatment of mental health disorders. Further policy changes and larger sample
study sizes might need to be enacted before full authorization; however, in use for
severe disorders with no alternative, compassionate use should be explored. The
ongoing search for more efficacious treatments in mental disorders that we do not fully
understand is imperative, so if hallucinogens can pave the way to better quality of life for
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